| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Leases Leasing > When Did This All Happen |
|
Answers - When Did This All Happen
I was driving my son to his 8th grade semi-final football game a couple of days ago when it struck me like a bolt of lightning. Sitting at a red light, the car in front of me, the cars to my left and right, and t According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product he car behind me...were all Toyotas. I stopped to ponder this and wondered what are the odds of being stuck at a light and being surrounded by 4 Japanese cars, all from the same manufacturer? Thirty years ago, I ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in would have taken the odds and placed the bet, but today, it is more common than we all probably realize. So, being a financial coach, I thought I should do some research and understand this phenomenon a little be lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ter. The facts I discovered are shocking to say the least, so fasten your seat belt and get ready for this... The stock market value (the market capitalization- all the shares of stock of a company multiplied by here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe the current stock price) of Ford Motors(F) and General Motors (GM) COMBINED is $34 billion.. Seems like a pretty decent number, right? Pull that seat belt a little snugger...the stock market value of Toyota Motor d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro (TM) is a staggering $193 billion!! Toyota Motors is worth 5 1/2 times the value of our two remaining American stalwarts COMBINED. 28 years in the investment business and I had no idea that it had gotten so out ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc of control. The investing world has voted and Toyota is the overwhelming winner. So let's peel back this onion a little more: what gives here? What happened and when did this all occur? Toyota will complete its easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi fiscal year 2007 on March 31, 2007, and its revenues will be about $196 billion, followed by March 31, 2008 at about $210 billion. The earnings per share (EPS) expectations for March 31, 2007 is $7.67 per shar nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically , and March 31, 2008, $8.45 per share. For a company of this massive size, 10% earnings growth is quite admirable. Shareholders equity at Toyota is $90 billion. All very impressive numbers. As for our two Ameri and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ an companies, the news is not so good, and the overall income statement numbers are a bit depressing. GM's revenues for calendar 2006/2007 are expected to be $170 billion for both years. Flat revenues, no growth ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi hatsoever. Ford's revenues for calendar 2006/2007 is also expected to be flat at $144 billion for both years. Ford will lose money this year and next, while GM is scheduled to be profitable for both years, but wi ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a th negligible growth. GM and Ford are saddled with huge long term debt, $285 billion and $154 billion, respectively; and very low shareholders equity at about $14 billion each. So where do we go from here? Toyo dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod a is the leader in developing the hybrid line of autos, half combustible engine, half electric. Consumer surveys are showing great confidence in Toyota's leadership position with the Hybrids. The Camry is also th cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin number one selling car in the United States; not the number one import--the number one seller period . Toyota's luxury line, Lexus, also leads the pack in customer satisfaction surveys and repeat buyers. Repeat tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen uyers has been the strategy of Toyota since the 1970's. Smother the customers with service, decent pricing and quality and guess what? They come back for more. Toyota sells each car at a profit. Their operations t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel are lean, efficient and cutting edge. Meanwhile, GM and Ford are hurting with exorbitant medical benefits costs to both their current workers and their retirees. Both companies have to play defense before they ca ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust n play offense. Both have begun the painful exercise of plant closings, layoffs and extreme cost cutting. It is their only way out of the financial quagmire both are mired in. Both GM and Ford have been rumoured y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products to be involved in merger discussions with several different European auto makers. It may be a necessary outcome for their survival. Both companies need a major cash rich, profitable partner to go the distance. I . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de redict that in the next 3-5 years, GM and Ford employess will be speaking a foreign language just to get along with their new partners or owners. Anybody remember Chrysler? Well, we got to my son's game a little elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip early...his team eeked out a victory. When we got back to our car to go out and celebrate (that's an ice cream treat for an 8th grader), guess what kind of cars were parked to my left and right? You guessed it... tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Medical Billing - GU0 Record Fields 18 Through 25 The Game, and How You Play It! 3 Options For Hosting Multiple Websites
|